Indication
Chronic Hepatitis B
The Chronic Hepatitis B pipeline: 42 tracked drugs, 9 approved for this indication.
9 approved / phase 46 Phase 311 Phase 25 Phase 1/28 Phase 13 preclinical / unstaged
Compare the share prices of listed companies in Chronic Hepatitis B →
Total attributable cost
$4.4B
$2,609/patient
Drug spend
Not yet sourced
any · US